αααααβααΎαDBV β’ FRA
add
DBV Technologies SA
1.89β¬
16 α§αααΆ, 10:59:57 PM ααααβααα +2 · EUR · FRA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
2.08β¬
α
αααααααααααα
1.89β¬ - 1.91β¬
α
ααααααα½αααααΆαα
α»αααααα
0.44β¬ - 2.00β¬
ααΎαβαα»αβααΈααααΆα
247.87Β ααΆα EUR
ααα ααα½αααΌαααααα
291.00
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
EPA
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 753.00Β ααΆαα | -46.48% |
α
αααΆαααααα·ααααα·ααΆα | 27.37Β ααΆα | -8.66% |
α
αααΌααα»ααα | -27.08Β ααΆα | 0.97% |
ααααΆααα
αααααα»ααα | -3.60ααΆαα | -85.03% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -0.23 | 91.18% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -25.67Β ααΆα | 9.96% |
α’ααααΆαααααααααΆαααααα·αααααΆα | β | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 12.96Β ααΆα | -87.23% |
ααααααααα»α | 50.56Β ααΆα | -65.34% |
ααΆαααα½ααα»αααααΌαααα»α | 47.69Β ααΆα | 39.27% |
ααΌαβααααα»α | 2.87Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 136.72Β ααΆα | β |
ααααααααααΉαααααα
| 69.33 | β |
ααα
ααααααΎαααααα | -114.52% | β |
ααα
ααααααΎααΎααα»α | -299.45% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -27.08Β ααΆα | 0.97% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -19.67Β ααΆα | 43.31% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -375.00Β ααΆαα | 82.41% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 45.00Β ααΆαα | 172.58% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -19.49Β ααΆα | 51.07% |
ααα αΌαααΆα
αααααΆααααααα | -9.34Β ααΆα | 66.16% |
α’αααΈ
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
ααΆααααααΎαα‘αΎα
29 ααΈααΆ 2002
αααααβαααααΆα
αα»ααααα·α
106
